SEHK:2617
SEHK:2617Biotechs

TransThera Sciences (Nanjing) (SEHK:2617): Assessing a Lofty Valuation After a 200% Three-Month Surge

TransThera Sciences (Nanjing) SEHK:2617 has quietly delivered a sharp move over the past 3 months, climbing more than 200%, which naturally raises the question of what the market is now pricing in. See our latest analysis for TransThera Sciences (Nanjing). That surge sits on top of an already extraordinary year to date, with a 726.38% year to date share price return. This suggests investors are rapidly repricing TransThera’s risk and growth prospects, even as near term swings remain...
SEHK:2498
SEHK:2498Electronic

How Investors May Respond To Robosense Technology (SEHK:2498) Mixed Q3 Loss Trend and Steady Revenue

Robosense Technology Co., Ltd has released its third-quarter 2025 results, showing CNY 407.11 million in sales with a wider quarterly net loss of CNY 101.04 million, while nine‑month sales rose to CNY 1,190.31 million and net loss narrowed to CNY 252.02 million compared with the prior year. The mix of stable quarterly revenue, a larger single‑quarter loss, and improved nine‑month loss figures offers a nuanced view of how Robosense’s cost structure and growth efforts are affecting its path...
SEHK:3690
SEHK:3690Hospitality

Meituan (SEHK:3690): Reassessing Valuation After Keeta Launch and Swing Back to Quarterly Net Loss

Meituan (SEHK:3690) just delivered a mixed third quarter update, with modest revenue growth but a swing from profit to a hefty net loss, right as it launches its new delivery platform, Keeta. See our latest analysis for Meituan. Despite the buzz around Keeta and Meituan’s push into new delivery formats, the 1 year total shareholder return of about -38 percent and steep year to date share price decline suggest sentiment is still cautious rather than momentum driven. If this kind of volatility...